265 related articles for article (PubMed ID: 29621625)
1. Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
McShane PJ; Weers JG; Tarara TE; Haynes A; Durbha P; Miller DP; Mundry T; Operschall E; Elborn JS
Pulm Pharmacol Ther; 2018 Jun; 50():72-79. PubMed ID: 29621625
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Kietzig C; Weimann B
J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):53-63. PubMed ID: 27448179
[TBL] [Abstract][Full Text] [Related]
5. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
[TBL] [Abstract][Full Text] [Related]
6. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
De Soyza A; Aksamit T; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371383
[TBL] [Abstract][Full Text] [Related]
7. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
[TBL] [Abstract][Full Text] [Related]
8. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
[No Abstract] [Full Text] [Related]
10. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
[TBL] [Abstract][Full Text] [Related]
11. Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties.
Liu C; Lin L; Huang Z; Wu Q; Jiang J; Lv L; Yu X; Quan G; Li G; Wu C
AAPS PharmSciTech; 2019 Jan; 20(2):85. PubMed ID: 30673901
[TBL] [Abstract][Full Text] [Related]
12. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Bilton D; Henig N; Morrissey B; Gotfried M
Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
[TBL] [Abstract][Full Text] [Related]
13. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
15. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
Dhand R
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
[TBL] [Abstract][Full Text] [Related]
16. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.
Stass H; Nagelschmitz J; Willmann S; Delesen H; Gupta A; Baumann S
Clin Drug Investig; 2013 Jun; 33(6):419-27. PubMed ID: 23605507
[TBL] [Abstract][Full Text] [Related]
17. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
18. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
[TBL] [Abstract][Full Text] [Related]
20. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
